Brind.

Novartis acquired Medicines Co., which was partnered with Alnylam. John Maraganore was a founder of Alnylam Pharmaceuticals.

2 reports, 2 independent Updated Sep 2

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Novartis acquired Medicines Co., which was partnered with Alnylam. John Maraganore was a founder of Alnylam Pharmaceuticals.

Who's involved

What this event is mainly about

Alnylam Pharmaceuticals Novartis

Keep exploring

The entities involved

Alnylam Pharmaceuticals
biopharmaceutical company
- Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.Mon 15:43
Novartis
Swiss-American multinational pharmaceutical corporation
- A study on cardiovascular health was presented at an American Heart Association meeting, sponsored by Novartis.Sat 16:37
- Novartis claimed a patent on an anti-cancer drug in 2012.Fri 13:24

Coverage

Newest first; wire copies grouped

Sep 2BioPharma DiveStartup Corsera Health aims to bring preventive heart medicine to the masses This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily Bio
Aug 27Business WireAlnylam to Webcast Presentations at Upcoming September Investor Conferences CAMBRIDGE, Mass., August 27, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeu